Jagdeesh Ullal is an Endocrinology/Metabolic physician affiliated with University of Pittsburgh. OpenAlex indexes 56 publications with 4,198 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 5th Ave Ste 3b
Suite 120
Pittsburgh, PA 152133403
Telephone
412-586-9700Provider last certified this registry record 25 Feb 2020.
Clinical trials
- Comparison of Meal-Time Dosing of Insulin in Cystic Fibrosis Related Diabetes
Sponsor: Jagdeesh Ullal
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year20251 payment
- Amgen Inc.Program year20242 payments
- Novo Nordisk IncProgram year20234 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
56.7%Insulin Analog19.3%Lantus Solostar36%Humalog Kwikpen U-10016%Novolog Flexpen13%Humalog11%Lantus7%Tresiba Flextouch U-1006%Insulin Lispro6%Novolog6%Part D<11 patientsGLP-1 receptor agonist12.5%Ozempic66%Trulicity20%Mounjaro14%Part D<11 patients+ 4 more classes in this area
Hormonal (systemic)
25.3%l-Thyroxine23.8%Levothyroxine Sodium87%Synthroid13%Part D<11 patientsThyroid Hormone Synthesis Inhibitor1.6%Methimazole100%Part D<11 patientsSensory organs
9.3%Corticosteroid9.3%Hydrocortisone100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Dexcom G7 Accuracy and Reproducibility in the Intensive Care Unit
Diabetes Technology & Therapeutics
2025 - Accuracy of Dexcom G6 Pro Continuous Glucose Monitor in the Intensive Care Setting: TIGHT ICU G6 Study
Diabetes Technology & Therapeutics
2025 - SGLT2 inhibitor therapy in overweight and obese patients with cystic fibrosis-related diabetes: Case series
Journal of Clinical & Translational Endocrinology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Toren Finkel, MD/PHD
University of Pittsburgh
Sally Wenzel, MD
University of Pittsburgh
Mary Phillips, MD
University of Pittsburgh
Jared Magnani, MD, MSc
University of Pittsburgh
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”